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Abstract
Background: The number of new leprosy cases reported annually is falling worldwide, but remains relatively high
in some populations. Because of the long and variable periods between infection, onset of disease, and diagnosis,
the recently detected cases are a reflection of infection many years earlier. Estimation of the numbers of sub-clinical
and clinical infections would be useful for management of elimination programmes. Back-calculation is a
methodology that could provide estimates of prevalence of undiagnosed infections, future diagnoses and the
effectiveness of control.
Methods: A basic back-calculation model to investigate the infection dynamics of leprosy has been developed
using Markov Chain Monte Carlo in a Bayesian context. The incidence of infection and the detection delay both
vary with calendar time. Public data from Thailand are used to demonstrate the results that are obtained as the
incidence of diagnosed cases falls.
Results: The results show that the underlying burden of infection and short-term future predictions of cases can
be estimated with a simple model. The downward trend in new leprosy cases in Thailand is expected to continue. In
2015 the predicted total number of undiagnosed sub-clinical and clinical infections is 1,168 (846–1,546) of which 466
(381–563) are expected to be clinical infections.
Conclusions: Bayesian back-calculation has great potential to provide estimates of numbers of individuals in health/
infection states that are as yet unobserved. Predictions of future cases provides a quantitative measure of
understanding for programme managers and evaluators. We will continue to develop the approach, and suggest
that it might be useful for other NTD in which incidence of diagnosis is not an immediate measure of infection.
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Background
Despite a large reduction in prevalence over the last half
century, leprosy remains a public health issue in many
countries [1]. In 2013 there were 215,000 new cases of
leprosy detected and reported worldwide, with 96 % of
these being detected in the 18 countries with the highest
burden [2]. Leprosy is caused by the bacterium Myco-
bacterium leprae and this infection can be cured
through the use of multidrug therapy (MDT). The drug
regimen is dependent upon the classification of the case:
paucibacillary cases receive six months of treatment with
two-drug MDT while multibacillary cases are treated for
12 months with three-drug MDT. Multibacillary cases
are identified as those with more than five skin lesions;
paucibacillary cases have five skin lesions or fewer. Out-
side of the Americas there is little published evidence of
transmission to humans from non-human reservoirs of
infection [3]. Taking this as evidence that non-human
reservoirs are not an important source of transmission,
then removing clinical, or sub-clinical, infection from
people by treatment should reduce the incidence of
infection.
In 1991, the World Health Assembly resolved to elim-
inate leprosy as a public health problem by the year
2000 [4]. The practical definition of this target was a
prevalence of less than 1 registered case per 10,000 of
the global population. Progress towards the target was
helped by the free provision of multidrug therapy (MDT)
from 1995 through the World Health Organisation
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(WHO), initially by the Nippon Foundation and since
2000 by Novartis. The global target was achieved, but lep-
rosy remains an important public health issue at a national
level for a number of countries and in some regions of
other (previously high burden) countries [5, 6].
Early diagnosis and use of MDT are the principle tools
used to combat leprosy [1]. The social stigma associated
with leprosy remains a barrier to early diagnosis, and
education is seen as an important step to overcome this.
The bacillus Calmette-Guérre (BCG) tuberculosis vac-
cine also has a protective effect against M. leprae infec-
tion [7], although the relative contribution of these
interventions to current control has not been quantified.
The latest WHO target for leprosy is a reduction in
the number of new cases with grade 2 disability to below
one per million of the global population by 2020 [5].
Grade 2 disability involves deformity of the hands or
feet, or severe visual impairment. The national number
of new cases with grade 2 disability is one of the vari-
ables reported annually to the WHO, along with the
total number of new cases and the number of new mul-
tibacillary cases.
We consider elimination as the process of reducing
the incidence of infection until transmission is zero. The
aim of modelling in the context of elimination is two-
fold. First, to provide quantitative forecasts of future
cases based on data and current understanding. Such
forecasts (made public) are essential as a test of
programme management and evaluation, and are an
early warning of changes in programme effectiveness.
Given the long and variable time periods between infec-
tion and disease in leprosy, the incidence of disease is a
biased measure of the incidence of infection (unless the
infection rate is constant). For example, when incidence
is exponentially decreasing, there is a bias towards indi-
viduals who have longer infection times [8]. Conse-
quently, changes in incidence of disease require
interpretation before they can be used to infer changes
in incidence of infection. The second, and most com-
mon, use of modelling for elimination is the prediction
of impacts of changes to control programmes, this type
of modelling has been applied to leprosy [9]. Here we
concentrate on the first of these aims: forecasting and
interpretation. The method we have chosen to use is
back-calculation [10], which provides estimates of past
incidence of sub-clinical infections, current prevalence
of (undiagnosed) sub-clinical and clinical infections and
short-term forward predictions of the numbers of new
detected and reported cases. Note that even if transmis-
sion is halted, cases will still arise in the future as in-
fected individuals progress through disease stages.
Back-calculation [10] has been used to study the infec-
tion dynamics of a variety of infectious diseases with
long and variable incubation period distributions, i.e. the
time between infection and diagnosis, for example HIV/
AIDS, BSE, vCJD, and also cancer. Each observed diag-
nosis is the result of a previous infection. Therefore,
given information on diagnoses and the incubation
period distribution (IPD), empirical estimates can be
made of the number of infections per time interval. The
diagnoses made during one interval are a mixture of in-
dividuals infected at different times in the past; for ex-
ample, individuals diagnosed in 2015 might include
people infected in the years 1990 to 2010, depending on
the infection rates in those years, and the IPD.
For discrete time periods, the basic back-calculation
equation is:
Di ¼
Xi
j¼1
Ij f i−j
where Di is the number of new diagnoses in the i
th time
interval, Ij is the expected number of infections in the j
th
time interval and fi−j is the probability that the time be-
tween infection and diagnosis is i-j time intervals. In the
simplest case fi−j comes directly from the IPD. The logic
of back-calculation is that given D and f, the convolution
above allows estimation of I. Here, we adopt a Bayesian
approach to estimate posterior densities, with a concen-
tration on estimation of variability in I as much as cen-
tral locations, and so include some variability in the time
period distributions, f, and estimate some relative fac-
tors. It is impossible to estimate both I and f simultan-
eously because of non-identifiability, but we can use
prior knowledge and external data to provide estimates
of I given uncertainty in f.
This basic model can be modified to reflect the natural
history of the disease under study. For example, AIDS
diagnosis was originally modelled as the end-point for
disease [10] but this has subsequently been refined to in-
corporate both AIDS and HIV diagnoses as well as a
number of other intermediate disease states based on
CD4 count [11].
Previous uses of back-calculation have concentrated
on epidemic or endemic situations (i.e. where I is in-
creasing or constant). In contrast, leprosy is globally de-
creasing, and back-calculation might be more generally
useful in disease control situations approaching elimin-
ation. In the case of leprosy, the time to diagnosis also
depends on the public health system in that more active
case finding will result in faster diagnosis. Consequently,
we will consider time-varying hazards associated with
the distribution of time from onset of symptoms to diag-
nosis, as well as time-varying rates of infection.
Methods
The endemic nature of leprosy and it’s long incubation
period mean that data on individuals’ time of infection
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are difficult to obtain. Consequently, information on the
IPD and the distribution of the time period from onset
of clinical symptoms to detection, the detection delay
distribution (DDD), must be obtained independently and
then incorporated into the back-calculation. Both the fit-
ting of distributions to time periods and the back-
calculation were implemented in a Bayesian Markov
Chain Monte Carlo (MCMC) setting. The program Just
Another Gibbs Sampler (JAGS) [12] was used, with the
R statistical environment [13] acting as the front end.
Fitting time period distributions
Data on time of infection, onset and diagnosis
Data on 49 individual cases of leprosy with short expos-
ure periods were extracted from the literature [14–20].
These were mostly military service personnel who spent
known, limited periods of time in endemic countries be-
fore returning to live in non-endemic communities and
subsequently being diagnosed.
Modelling time period distributions
For each individual, the observed endpoints for each
time period (onset of symptoms and diagnosis) were
modelled as to = ti + pi:o and td = ti + pi:o + po:d, re-
spectively, where ti was the unobserved time of infection
and pi:o and po:d were the periods from incubation to on-
set and from onset to diagnosis. Infection time was a
uniformly distributed variable between the start and end
of exposure and the two time periods were gamma dis-
tributed random variables. The observed values, to and
td, were both left and right censored, with onset and
diagnosis dates taken as being known to within some
time interval. The Gibbs Sampler was used to obtain
samples from the posterior probability distributions of
the shape and rate parameters of the gamma distributions.
Back-calculation
National incidence of new leprosy cases
The data used consisted of annual numbers of new
leprosy cases, new multibacillary leprosy cases and
new leprosy cases with grade 2 disability reported at
the national level for Thailand. These data were taken
from published reports [2, 21–28]. The variables re-
ported to the WHO have changed over time, resulting
in the number of new cases detected, number of new
cases with grade 2 disability and the number of new
multibacillary cases being available from 1965, 1982
and 1984, respectively. Data on the three variables
were available up to 2014. Since 1993, cases of multi-
bacillary leprosy have been identified via case classifi-
cation (with >5 skin lesions indicating a multibacillary
case) rather than a bacterial index score. The transi-
tion from the use of the bacterial index to case classi-
fication took place from 1989 to 1993. From 1984 to
1988 the number of new lepromatous leprosy cases
identified under the Madrid classification system [29]
was used as the count of new multibacillary cases
[21]. The observed values are plotted against year in
Fig. 1.
Back-calculation model
The progression from sub-clinical to clinical infection
and subsequent diagnosis of leprosy was described by
a discrete time period model. Calendar years were
used as the discrete time step, in keeping with the
annual reporting of national summary information to
the WHO. The time period of the analysis was set to
start 30 years before the first observed record, to
Fig. 1 Observed and predicted numbers of new leprosy cases, new
multibacillary cases and new cases with grade 2 disability by year for
Thailand. Predicted values are modes and 95 % highest posterior density
intervals. The cut-offs between different diagnosis effort/effectiveness levels
are indicated by blue vertical lines
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allow the system to generate an appropriate pattern
of infection to explain the early observations, leprosy
being an endemic disease.
The expected incidence of infections in year b was
simulated with a random walk process. The observed
number of infections in year b was modelled as:
Ib∼Poisson λbð Þ
where prior distributions for the λb were
λb ∼
Uniform 0; 10000ð Þ if b ¼ 1
N λb−1; σ2ð Þ; λb > 0 if b > 1

The standard deviation, σ, used in the random walk
process was set to 30 for the analyses reported in the
paper. This was chosen from a number of test runs of
the model to provide a smooth downward curve of in-
fections over time while still maintaining some variation.
There is no information in the data to allow σ to be esti-
mated within the analyses.
Progress from sub-clinical infection to the onset of
symptoms was controlled by the IPD, a gamma distribu-
tion with constant parameters within a single MCMC
chain. The parameters of the IPD were taken from the
analyses reported here. From the numbers of sub-
clinical infections, the expected number of new clinical
infections in any year can be calculated using the IPD:
E Oc½  ¼
Xc
b¼1
Ibf c−b
Where fc-b was the probability that time between sub-
clinical infection and onset of clinical symptoms was c-b
years. The observed number of clinical infections in year
c was then Oc ∼ Poisson (E[Oc]).
There is no test for sub-clinical leprosy. Therefore,
diagnosis occurs subsequent to the onset of symptoms
in the model. The probability of being diagnosed in
any year given that onset occurred in some known
previous year was derived from the onset to diagnosis
time period distribution; again using a gamma distri-
bution with constant parameters within a single
MCMC chain with the parameters taken from the
separate time period fitting reported in this paper.
We additionally added a parameter reflecting the ef-
fort being put into diagnosis at that time (i.e. scaling
the diagnosis hazard for that year).
Variations in the effort put into diagnosis pro-
grammes, or the effectiveness of these programmes, is
handled by scaling the hazard of being diagnosed in
year d given that onset of clinical symptoms occurred
in year c (hdc). The probability of an individual being
diagnosed in year d given that the onset of clinical
symptoms was in year c is:
gdc ¼ γkhdc 1−Gdcð Þ
Where Gdc ¼
Xd−1
i¼1
gic , diagnosis effort is modelled by γk
and hdc comes from the DDD:
hdc ¼ Prob c−1 ≤ X < cð Þ1−Prob X < c−1ð Þ
For the Thailand data, six different effort parameters
were included to correspond to periods in which the
diagnosis effort or effectiveness may have differed [21],
as set out in Table 1. The effort parameters, γk, were
modelled using a random walk, such that effort in period
k was a change from the effort in the previous period.
The prior distributions for γk were:
γk ∼
Uniform 1; 0:252
 
if k ¼ 1
N γk−1; 0:252
 
if k > 1

The expected number of diagnoses in year d was then:
E Dd½  ¼
Xd
j¼1
E Oj
 
gdj
The observed number of new diagnoses in year i was a
Poisson variable with parameter E[Di], Di ∼ Poisso-
n(E[Di]). The probability of a multibacillary diagnosis be-
ing made in year d given that onset of clinical symptoms
happened in year c was assumed to be unrelated to both
the length of time since onset and calendar time; fdc
M =
ϕMifdc, where ϕMi was the proportion of multibacillary
cases expected in the ith period (d < 1989, 1989 ≤ d ≤
1993 and d ≥ 1994) and fdc was the probability of being
diagnosed in year d given that the onset of clinical symp-
toms occurred in year c. The same prior was used for all
three ϕMi, ϕMi ∼ Beta(2, 2).
The existence of a relationship between the proportion
of grade 2 disability cases and detection delay has been
demonstrated previously [30]. This relationship was in-
corporated into the back-calculation model as a linear
regression on detection delay. The probability of a new
case with grade 2 disability being made in year d given
that onset of symptoms happened in year c was taken to
be fdc
D =min(ϕD + (d − c + 1)κD, 1)fdc. Uniform priors
were assumed for ϕD and κD, ranging from zero to 0.25
for both parameters.
The uncertainty about the parameters associated with
the IPD and DDD was incorporated into the back-
calculation via multiple imputation [31] to avoid prob-
lems arising from the lack of information in reported
case data on the parameters of the IPD and DDD. Mul-
tiple MCMC chains were run, with each one using a
randomly sampled set of parameters from a multivariate
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normal approximation to the posterior probability distri-
bution of the IPD and DDD parameters. A total of 100
chains were run, with 50 samples being retained from
each. Each chain was run for 250,000 iterations; after
25,000 adaptation and 150,000 burn-in samples one out
of every 1,500 samples was retained. The resulting 5,000
samples were merged to provide an overall posterior
probability distribution for the parameters of interest.
The chains were given equal weight in the merging as
they were expected to fit the data equally well.
Results
Time period distributions
The IPD and DDD were fitted as gamma distributions
with a common rate parameter. In this way the distribu-
tion of the sub-clinical infection to detection period is
also a gamma distribution with the same rate parameter
and a shape parameter equal to the sum of the shape pa-
rameters of the two constituent distributions. Table 2
contains a summary of the posterior probability distribu-
tions of the three parameters. The parameters are
strongly correlated with each other and these relation-
ships were taken into account in the back-calculation.
This was done through the use of a multivariate normal
approximation to the joint posterior probability distribu-
tion of these parameters from which samples were
drawn for the multiple imputation runs.
The posterior samples of the time period distribution
parameters were used to generate samples of the gamma
density for each curve at each time point. These were
used to create Fig. 2, which shows the mode and 95 %
highest posterior density interval (HPD95) of the two
distributions. The modal value of the IPD was 3.8 years
(HPD95: 2.10 to 5.64 years). For 95 % of infected indi-
viduals, onset occurs by 17.8 years after infection (modal
value, HPD95: 15.2 to 22.3 years). Detection occurred
for 95 % of clinical infections by 11.4 years post-onset
(modal value, HPD95: 9.4 to 14.9 years). The mode of
the sub-clinical infection to diagnosis period distribution
was at 7.9 years (HPD95: 5.9 to 9.7 years), and 95 %
of clinical infections were detected by 23.6 years after
sub-clinical infection (modal value, HPD95: 20.4 to
29.2 years).
Trends in cases
Figure 3 shows the predicted trends in the numbers of
new sub-clinical and clinical infections and reported
cases for 1950–2025. The trends in sub-clinical infec-
tions and clinical infections are smooth with the clinical
infection curve lagging the sub-clinical infection curve
slightly.
The diagnosis hazard in any year is scaled by a diag-
nostic effort parameter, and this enables the trend in
new diagnoses to follow the observed data points rea-
sonably well (Fig. 1). The posterior probability distribu-
tions of the six effort parameters are in Fig. 4. During
the period where leprosy care was being incorporated
into the general health care system and workers were
being trained (1972–1977), fewer diagnoses were being
made than would be predicted based on the DDD. The
modes of the parameter distributions for the other five
intervals are above 1, indicating that more diagnoses are
made than predicted just using the DDD estimated
previously. In particular, the highest diagnostic effort/
effectiveness was before 1972, when leprosy care joined
the general health care system.
Figure 1 shows the predicted numbers of new cases,
new multibacillary cases and new cases with grade 2 dis-
ability along with the observed numbers and the cut-offs
for different periods of diagnostic effort. The observed
values are quite well predicted by the analysis.
The scale which results from the large reduction in
the number of new cases over recent decades prevents
the variation of the posterior probability distribution
Table 2 Summary of posterior probability distributions of the
shape parameters for the incubation period and detection delay
distributions (αi:o and αo:d) and the common rate parameter (β)
Parameter Mode 95 % Highest Posterior
Density Interval
Correlation with
αi:o αo:d
αi:o 2.03 1.37 to 2.71
αo:d 1.03 0.73 to 1.37 0.59
β 0.25 0.18 to 0.34 0.80 0.72
The incubation and detection delay periods are assumed to be Gamma
distributed with a common rate parameter such that the interval from
sub-clinical infection to diagnosis is also Gamma distributed with shape
parameter αi:o + αo:d and rate parameter β
Table 1 Periods for which the effort or effectiveness of diagnosis may have varied in Thailand, corresponds to parameters fitted
Diagnosis year, d Why
d < 1972 In 1971 leprosy treatment moved into general health-care services
1972≤ d < 1977 On-going training of health-care workers, so possible loss of effectiveness
1977≤ d < 1984 In 1984 WHO introduced multidrug therapy (MDT), so this period uses general health-care services but no MDT
1984≤ d < 1992 Both general health-care services and treatment by MDT
1992≤ d < 2001 1991: global target set of 1 new case per 10,000 of population by 2000
d≥ 2001 Past the cut-off for the global target, possible change in effort
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being as clear as it would be in close-up, but there is an
increase in variation after 2014, when the observations
end.
Prevalence of infection
In line with the observed decline in new cases, the cu-
mulative burden of undiagnosed infections, both sub-
clinical and clinical, has also reduced over time (Fig. 5).
As the incidence of diagnoses falls, so the uncertainty in
numbers of undiagnosed sub-clinical and clinical infec-
tions reduces. The uncertainty in incidence of sub-
clinical infection in the very recent past (see Fig. 3)
contributes to slightly increasing uncertainty in preva-
lence in the very recent past. However, the uncertainty
in the recent past is largely determined by the choice of
σ in the random walk.
Forecasting of diagnoses
The back-calculation analysis was run excluding data
from 2010–2014, in order that these could be predicted
(Fig. 6). As with the analysis of the full data, 100 samples
were taken from a multivariate normal approximation to
the posterior probability distribution of the parameters
of the IPD and DDD and included via multiple imput-
ation. The predictions of new cases, new multibacillary
cases and new cases with grade 2 disability show the
correct trend, but a number of observations lie outside
of the HPD95 of their predicted values.
Discussion
We have developed a back-calculation approach to re-
construct the past incidence of infection with leprosy in
Thailand. This approach also predicts the numbers of in-
dividuals with sub-clinical and clinical leprosy who are
yet to be diagnosed, and also future predictions of
diagnoses of different types. We believe that these re-
sults demonstrate the value of this approach.
Time period distributions
The use of our estimated time period distributions (IPD
and DDD) in the back-calculation analysis is a major
source of assumptions. It is assumed that the time
period distributions are invariant over time, between
sexes and between ages of infected individuals. This is
reflected in the transition from sub-clinical infection to
clinical infection being completely mediated by the IPD.
The assumptions around the DDD are even greater, as-
suming that detection delays will be far more specific to
a country/region and time period. The assumptions
about the DDD are mitigated by scaling the hazard asso-
ciated with diagnosis years to reflect the effort put into,
and effectiveness of, case detection. Future work will
consider how to extract additional information on time
period distributions, particularly as infection rates drop
to zero then the last cases are more reflective of the
distribution.
Trends in cases
The annual trends in numbers of new sub-clinical infec-
tions and clinical infections were smooth curves, with
the new clinical infection trend lagging the sub-clinical
infection trend slightly. This is expected from the use of
an invariant IPD, with nothing else contributing to the
hazard of onset of clinical symptoms in any year. The
variation in the number of new infections per year is
constrained by the choice of standard deviation associ-
ated with the random walk. A number of test runs were
performed and a value of 30 was chosen which gave a
smooth curve without allowing the new sub-clinical in-
fections to be over-reactive to the observations. It might
be more realistic to scale the standard deviation of the
Incubation period Detection delay
0.0
0.1
0.2
0.3
0 10 20 30 0 10 20 30
Time (years)
D
en
si
ty
Mode
HPD95
Fig. 2 Mode and 95 % Highest Posterior Density intervals (HPD95) of the density of incubation period distribution and detection delay
distribution. The y-axis is truncated. The upper limit of HPD95 for the density of the detection delay distribution is infinite at time zero
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random walk in accordance with the number of new in-
fections and this will be investigated in the future. One
suggestion is the use of a gamma distribution random
walk in which the expected number of new sub-clinical
infections in year b would be λb∼Gamma k; kλb−1
 
. The
choice of standard deviation in the current random walk
largely controls the amount of uncertainty in the inci-
dence of sub-clinical infection (and hence prevalence of
sub-clinical infection) in the very recent past. This is es-
sentially unobservable (i.e. sub-clinical infections yesterday
will have no impact on diagnoses for a number of years),
so the bounds are effectively 0 to the total population.
The highest estimated diagnostic effort/effectiveness
parameter corresponded to the period before leprosy
care joined the general health care system, which took
place after 1971 [21]. This may reflect a relatively lower
level of expertise of diagnostic clinicians in the general
health care system leading to longer average detection
delays. The diagnostic effort parameters express the ef-
fort/effectiveness of the programme relative to a value of
one, when the DDD would be the sole determining fac-
tor. The effort parameters are therefore dependent upon
the specific time period distribution used, which in our
case would reflect the predominant health care system
at the time of diagnosis of our small sample of individ-
uals with information on the time of sub-clinical infec-
tion, onset of clinical symptoms and detection.
Fig. 3 Predicted trends in new sub-clinical infections, clinical infection
and detections in Thailand
0
2
4
6
0.5 1.0 1.5
Parameter value
D
en
si
ty
Diagnosis year (d )
d < 1972
1972 ≤ d < 1977
1977 ≤ d < 1984
1984 ≤ d < 1992
1992 ≤ d < 2001
d ≥ 2001
Fig. 4 Posterior probability distributions of diagnostic effort/effectiveness
parameters in Thailand
Fig. 5 Predicted trends in cumulative numbers of undiagnosed
infections in Thailand
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The models relating to the occurrence of multibacil-
lary and grade 2 disability cases are very simple, but ap-
pear to fit quite well. Additional data would be required
to allow investigation of more sophisticated relationships
between the incidence of multibacillary or grade 2 dis-
ability cases and the detection delay, incubation period
and other possible risk factors. The results of analyses of
these additional data would then be incorporated into
the back-calculation rather than trying to estimate the
parameters within the back-calculation from little or no
information.
Prevalence of infection
Note that we are only able to estimate cases of infection
that are eventually diagnosed in Thailand. If a significant
number of infections resolve spontaneously or do not
progress to clinical disease, then our results will under-
estimate the true numbers of infections. Similarly, if
there is significant migration of infections between
countries, then our results are less interpretable. In our
current model, the cumulative burden of undiagnosed
clinical infections is not related to the number or rate of
new sub-clinical infections, which might be expected in
reality as leprosy is transmissible. This is inherent in the
current approach to the analysis; in which infection
leads to onset and subsequent diagnosis with no mech-
anism by which the burden of infection impacts upon
the number of future new infections. Future work will
consider whether it is feasible to make the incidence of
sub-clinical infection a function of the prevalence of
clinical, or sub-clinical, infection.
Forecasting of diagnoses
Our preliminary attempts to forecast cases from 2010–
2014 reproduced the decreasing trend but do not fully
reflect the variation in the observed values, with several
observations falling outside the HPD95 of their pre-
dicted values. Given the simplicity of our model, in
particular for the prediction of the numbers of new mul-
tibacillary cases and new cases with grade 2 disability,
this appears to have been quite successful. Future work
will include refining the model, including with respect to
predicting the numbers of new multibacillary cases and
grade 2 disability cases reported. This may require add-
itional data to enable the investigation of parameters as-
sociated with some aspects of the model external to the
back-calculation, as has been done in other studies [32].
Reaching the 2020 goal
The goal for 2020 is a reduction in the annual number
of new cases with grade 2 disability to below 1 per mil-
lion of the global population. United Nation predictions
of the population of Thailand in 2020 have a 95 % prob-
ability interval from 67.8 to 69.4 million, with a median
value of 68.6 million [33]. The cut-offs for 1 new case
with grade 2 disability per million people are therefore
from 67.8 to 69.4. Our observations are that this has
already been achieved within Thailand, and that the pre-
dicted 95 % highest probable density interval of the
number of new grade 2 disability cases in 2020 goes
from five to 22, with a mode of 13. While it is not pos-
sible to extrapolate from predictions for a single country
to the global leprosy situation, more meaningful obser-
vations about the 2020 goal will be possible when
equivalent analyses are run on data from the countries
reporting the majority of the world’s new cases for lep-
rosy. This will constitute a major part of the next phase
of our research programme.
Conclusions
Based on this initial analysis the Bayesian back-
calculation approach shows much promise as a tool to
provide insights into numbers of individuals with sub-
clinical or clinical leprosy infections but as yet undiag-
nosed. Predictions of the expected number of future
Fig. 6 Forward prediction and reported annual numbers of new leprosy cases, multibacillary cases and cases with grade 2 disability from 2010 to
2014. Posterior probability distributions for predicted values came from running the back-calculation model excluding the observed values for 2010–2014
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diagnoses may help to provide some understanding of
the elimination process.
Our model remains under development. As well as
making improvements around the current analysis, in-
fection incidence by age and gender remain to be incor-
porated. Differences associated with the infection to
onset and onset to diagnosis time period distributions
associated with time, age and gender are also being
considered.
We suggest that there may be value of using this
method of analysis for other neglected tropical diseases
in which the incidence of diagnosis is not an immediate
measure of infection.
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